title: AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection.
abstract: Correlates of immune protection from HIV vaccines remain undefined. The first HIV vaccine efficacy trial in the US and Europe VAX004, was designed to assess whether rgp120 envelope subunits (AIDSVAX B/B, VaxGen) can induce partial or complete protection from HIV-1 infection. No effectiveness in the reduction of either the acquisition of infection or levels of plasma viremia after HIV infection was noted. We found evidence of vaccine-specific CD8+ T cells in volunteers who received the vaccine, regardless of behavioral risk. Surprisingly, the CD8-response is significantly higher in participants who would go on to contract HIV infection. These results suggest that AIDSVAX immunization may boost preexisting immune responses-due to pre-infection exposure, and a vaccine-induced immune profile may serve as a biological marker for HIV susceptibility.
authors.affiliation: California Department of Public Health, Richmond, CA 94804, United States. Norman.Jones@cdph.ca.gov
authors.forename: Norman G
authors.initials: NG
authors.lastname: Jones
authors.forename: Allan
authors.initials: A
authors.lastname: DeCamp
authors.forename: Peter
authors.initials: P
authors.lastname: Gilbert
authors.forename: Michael L
authors.initials: ML
authors.lastname: Peterson
authors.forename: Marc
authors.initials: M
authors.lastname: Gurwith
authors.forename: Huyen
authors.initials: H
authors.lastname: Cao
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D004198:Disease Susceptibility; D005060:Europe; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D006805:Human Experimentation; D006801:Humans; D008875:Middle Aged; D014481:United States; D014766:Viremia / Q000517:prevention & control; D055815:Young Adult
chemical_list: D016915:AIDS Vaccines; C112734:AIDSVAX